Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 8,376 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Capsule Endoscopy for HEmorrhage in the ER

NCT03458000
View directory record Official record
Conditions
Upper Gastrointestinal Bleeding
Interventions
PillCam UGI, Standard of Care
Device · Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

NCT00051636
View directory record Official record
Conditions
Paget's Disease of Bone
Interventions
Zoledronic Acid, Risedronate, Placebo to Risedronate, Placebo to Zoledronic Acid, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
12
States / cities
Santa Monica, California • Lakewood, Colorado • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

NCT03436199
View directory record Official record
Conditions
Walking Impairment, Multiple Sclerosis
Interventions
ADS-5102, 137 mg, ADS-5102, 274 mg, Placebo
Drug · Other
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
78
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

INDV-2000 First in Human

NCT04413552
View directory record Official record
Conditions
Opioid Dependence
Interventions
INDV-2000, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Fat Malabsorption in Chronic Pancreatitis

NCT02849704
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Creon36™
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
30 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 25, 2026, 9:39 PM EDT
Terminated Phase 2 Interventional Results available

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

NCT00302952
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lovastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 2 Interventional Results available

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01103349
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo, Montelukast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Metformin During Nicotine Withdrawal

NCT03593538
View directory record Official record
Conditions
Smoking, HIV-1-infection
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.

NCT01995643
View directory record Official record
Conditions
Polyphenolic Compounds and Metabolism
Interventions
Active Capsule, Placebo Capsule
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

NCT03542435
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SXC-2023, Placebo
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

NCT02232308
View directory record Official record
Conditions
Gastroparesis
Interventions
Nizatidine, Lisinopril, Placebo
Drug
Lead sponsor
Adil Bharucha
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01124708
View directory record Official record
Conditions
ADHD
Interventions
TC-5619-238, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
16
States / cities
Bradenton, Florida • Jacksonville, Florida • Lauderhill, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 25, 2026, 9:39 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Study to Evaluate EnteroTracker® as a Sampling Method to Screen for Barrett's Esophagus/Esophageal Cancer

NCT05706025
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
EnteroTracker
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 25, 2026, 9:39 PM EDT
Terminated Phase 3 Interventional

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

NCT00658008
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Litchfield Park, Arizona • Costa Mesa, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2012 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Not applicable Interventional

Efficacy of Vitamin D Supplementation in Obese Children

NCT02956408
View directory record Official record
Conditions
Obesity, Pediatric, Obesity, Childhood, Obesity, Morbid, Vitamin D Deficiency
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 11 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Early Phase 1 Interventional

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

NCT03295240
View directory record Official record
Conditions
Mantle Cell Lymphoma, Lymphoma
Interventions
BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 25, 2026, 9:39 PM EDT
Terminated Phase 2Phase 3 Interventional

A Long-Term, Open-Label, Study on Schizophrenia

NCT01129674
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Not applicable Interventional

Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye

NCT00883649
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Hydroeye, Inactive Capsule
Dietary Supplement · Other
Lead sponsor
Virginia Eye Consultants
Other
Eligibility
40 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phlebotomy Study of Testosterone Undecanoate

NCT02670343
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Abuse Potential of Cebranopadol in Humans

NCT05256108
View directory record Official record
Conditions
Human Abuse Potential
Interventions
Oxycodone 40 mg, Tramadol 600 mg, Placebo, Cebranopadol 600 µg, Cebranopadol 1000 µg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 25, 2026, 9:39 PM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

NCT02891408
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Firsocostat, Fenofibrate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT03877510
View directory record Official record
Conditions
Parkinson Disease
Interventions
IPX203
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
50
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 25, 2026, 9:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

NCT01979484
View directory record Official record
Conditions
Pharmacokinetic Assessments in Healthy Volunteers
Interventions
PPI-668 capsule, PPI-668 tablet
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 25, 2026, 9:39 PM EDT